Article
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2015
Wong A L, Soo R A, Tan D S, Lee S C, Lim J S, Marban P C, Kong L R, Lee Y J, Wang L Z, Thuya W L, Soong R, Yee M Q, Chin T M, Cordero M T, Asuncion B R, Pang B, Pervaiz S, Hirpara J L, Sinha A, Xu W W, Yuasa M, Tsunoda T, Motoyama M, Yamauchi T, Goh B C
Abstract excerpt
BACKGROUND: The aim of this study was to determine the maximum-tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of OPB-51602, an oral, direct signal transduction activator of transcription 3 (STAT3) inhibitor, in patients with refractory solid tumors. PATIENTS AND METHODS: Thr...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.